Background: Although calcium channel blockers (CCB) are highly effective for suppression of vasospastic angina (VSA) attacks, their prognostic effects in VSA patients remain to be examined in a large number of patients.
he prevalence of coronary vasospasm is high in Japanese patients with ischemic heart disease 1,2 and acute myocardial infarction (AMI). 3 Therefore, the control of vasospastic angina (VSA) has been an important clinical issue in Japan. 4-7 Calcium channel blockers (CCB) have been widely used to suppress VSA attacks and to improve the outcome of VSA patients. 4,8, 9 However, comparison of the prognostic effects of CCB in VSA patients remains to be performed in a large number of patients. During the past decades, several observational studies showed that the outcome of VSA patients vary, depending on the CCB used. 10- 14 In the 1980s, it was shown that 80-90% of VSA patients were treated with CCB and the major adverse cardiovascular events (MACE) rate was relatively low during the 5-year follow-up. 8 Recently, the usage of CCB has further increased to 90-95% unless otherwise contraindicated. Thus, in order to compare the actual difference among the major CCB, it is necessary to perform a large-scale clinical trial. Another possible approach is to perform a meta-analysis, utilizing the database created from previously published papers that compared the prognostic effects of CCB. In the present study, we thus performed a meta-analysis in which we compared the prognostic effects of CCB in Japanese patients with VSA.
by the database of Ichushi ® ( Figure 1B) . Permission to perform a meta-analysis was obtained from the authors of the selected 4 papers. 10- 13 We asked them to provide unlinkable, anonymous raw data (database), which we used to create a new database. This enabled us to analyze the data from 1,997 VSA patients with positive response to coronary spasm provocation tests. The coronary spasm provocation test was considered positive when an ischemic ECG changes and/or chest pain with coronary constriction was induced by intracoronary administration of acetylcholine or ergonovine, based on the 2008 Guidelines of the Japanese Circulation Society. 15 In the present study, the baseline point was defined as the day of discharge after the diagnosis of VSA, and the follow-up period was redefined from the 4 papers.
Comparison of CCB Treatments
Among the 1,997 VSA patients, 1,554 (77.8%) were treated with CCB, including benidipine (n=320), amlodipine (n=308), nifedipine (n=182) and diltiazem (n=960) ( Figure 1 . Summary of identification and selection of previous papers. According to the keywords, papers were systemically searched from (A) the database of MEDLINE ® for English articles (from 1950 to 2008), and (B) from the database of Ichushi ® (Japana centra revuo medicina) for Japanese articles with an English abstract (from 1983 to 2008). VSA, vasospastic angina; CCB, calcium channel blockers. 
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those treated with CCB, 1,349 patients were treated with a single CCB, including benidipine (n=219), amlodipine (n=199), nifedipine (n=143) and diltiazem (n=788). As the number of VSA patients treated with other CCB was small, these patients were excluded for comparison of the 4 CCB, although they were included in the whole meta-analysis. For patient characteristics, we examined the baseline data on age, gender, body mass index (BMI), smoking, family history of ischemic heart disease, risk factors (hypertension, diabetes mellitus, and hyperlipidemia), previous myocardial infarction (MI), left ventricular ejection fraction (LVEF), and the presence of significant coronary artery disease (CAD, 75% or greater coronary stenosis on coronary angiography). Cotreatment with other class of drugs also was examined, including nitrate preparations, nicorandil, statins, angiotensin II receptor blockers (ARB), angiotensin converting enzyme (ACE) inhibitors and β-blockers. The data for age, BMI and LVEF were handled by the use of categorization (age, 10-year intervals; BMI, ≥22.5 kg/m 2 ; LVEF, <45%). (8) 24 (8) 26 (14) 93 (10) (12) 46 (15) 24 (13) 124 (13) 2 VD 16 (5) 9 (3) 6 (3) 32 (3) 3 VD (22) 53 (17) 47 (26) 164 (17) 0.015 Aspirin 48 (15) 44 (14) 17 (9) 131 (14) 0.594 Statins 33 (10) 32 (10) 15 (8) 86 (9) 0.598 ARB 17 (5) 30 (10) 8 (4) 36 (4) 0.004 ACE inhibitors 33 (10) 36 (12) 15 (8) 51 (5) 0.001 β-blockers 34 (11) 33 (11) 14 (8) 67 (7) 0.076 BMI, body mass index; IHD, ischemic heart disease; MI, myocardial infarction; LVEF, left ventricular ejection fraction; VD, vessel disease; ARB, angiotensin II receptor blockers; ACE, angiotensin converting enzyme. NISHIGAKI K et al.
Outcomes
The major outcome in this study was the occurrence of MACE, including cardiac death, MI (fatal and non-fatal), heart failure (death due to heart failure and heart failure requiring hospitalization), stroke (fatal and non-fatal), and aneurysm. The incidence of each MACE and the total number of deaths due to the event and its percentage were calculated for each CCB. We compared each MACE occurrence between the patients treated with each CCB and those without it. Because some differences were observed in the patient characteristics at baseline among the CCB groups, a search for factors (characteristics of patients and drugs used) that affected the occurrence of MACE was performed. The effect of the treatment with each CCB on the occurrence of MACE was then corrected for the factors that could have affected the occurrence of MACE.
Statistical Analysis
The major outcome of the present study was the occurrence of MACE. For each CCB, the period from the baseline day to the occurrence of MACE or the day of the last follow-up were plotted as a Kaplan -Maier curve, comparing the patients treated with each CCB and those without it. The curves were analyzed using the log-rank test. To search for factors related to the occurrence of MACE, the hazard ratio (HR) and its 95% confidence interval (CI) were calculated using Cox's regression analysis. The effect of the treatment with each CCB on the occurrence of MACE was corrected by Cox regression analysis using the factors that could affect the MACE occurrence (eg, smoking and a history of MI). In addition, in the 1,349 patients treated with a single CCB, the period until the occurrence of MACE was plotted in each CCB group as a Kaplan -Maier curve and compared using the log-rank test. All results are presented as means ± SD. All statistical analyses were performed using SPSS for Windows ver. 11.0.1 (SPSS Japan Inc, Tokyo, Japan). Significance levels of 5% bilaterally and P-value less than 5% was considered to be statistically significant.
Results

Patient Characteristics
In the 4 papers used in the present meta-analysis, the diagnosis of VSA was made based on the 2008 Guidelines of the Japanese Circulation Society ( Table 1) . 15 As a result, the number of VSA patients reported by Io et al. 11 was changed from 1,047 to 879, and a total of 1,997 VSA patients with positive response to coronary spasm provocation tests were 
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finally analyzed. In addition, because the events used for the outcome evaluation varied slightly among the 4 papers, all of the events evaluated were handled as complex events. The follow-up period was recalculated according to the definition of MACE used in the present study, with a median follow-up period of 4.4 years (min -max: 0.2-21.9). Table 2 shows the clinical characteristics of the VSA patients treated with each CCB. The age was higher in the benidipine group compared with other CCB groups. The prevalence of female patients was higher in the benidipine group compared with the nifedipine group. Among the major risk factors, hypertension was less frequent in the diltiazem group and hyperlipidemia was less frequent in the diltiazem or nifedipine groups compared with other CCB groups. Previous MI was observed more frequently in the nifedipine group. Regarding the concomitant drugs, nitroglycerin preparations were used less frequently in the benidipine group compared with other CCB groups, and nicorandil was more frequently used in the benidipine and nifedipine groups compared with other 2 groups. ARB were used more frequently in the amlodipine group compared with the nifedipine or diltiazem groups, while ACE inhibitors were less frequently used in the diltiazem group. Nifedipine was the long-acting form (twice a day or once a day), and diltiazem was slow-release preparation.
We also compared the reduction in the frequency of anginal attacks due to coronary spasm in the 4 CCB groups. We found that the frequencies of anginal attacks at follow up in the benidipine (0.7±1.1 attacks/month) and nifedipine (0.7± 1.6 attacks/month) groups were significantly lower than those in the amlodipine (1.4±1.6 attacks/month) and diltiazem (1.6± 5.9 attacks/month) groups (P<0.001, between each group, Mann -Whitney test).
Comparison of the Prognostic Effects of CCB
In the present study, MACE occurred in 143 patients, including cardiac death (n=36), AMI (n=51), heart failure (n=26), stroke (n=65) and aortic aneurysm (n=11). The total number of deaths was 118. Of these events, the number of each event observed in VSA patients treated with either of 4 CCB, ie, benidipine, amlodipine, nifedipine and diltiazem, was shown in Table 3 . MACE occurred significantly less in the patients treated with benidipine compared with those without it (P= 0.031, log-rank test) (Figure 2) . By contrast, no significant difference was noted between the patients treated with amlodipine, nifedipine or diltiazem and those without them (Figure 2) . A search for the background factors that could have affected the occurrence of MACE showed significant differences with respect to age (10-year intervals), the presence of diabetes mellitus, the presence of CAD, and use of β-blockers ( Table 4) . The HR for the occurrence of MACE was significantly lower in the patients treated with benidipine compared to those without benidipine (HR =0.46, CI = 0.22-0.95, P=0.035) (Figure 3) . The HR was also significantly lower in the patients treated with benidipine, even after correction for the background factors (HR =0.41, CI =0.20-0.85, P=0.016) (Figure 3) . Again, no significant difference was noted with other 3 CCB (Figure 3) .
Multivariate analysis showed that diabetes mellitus and CAD were independent risk factors for MACE. However, age and use of β-blockers had no significant impact on the Figure 3 . Influence of calcium channel blockers on major adverse cardiovascular events (MACE) in vasospastic angina patients (Cox regression analysis, n=1,997 in total). No, number; pts, patients. *The factors used for the adjustment included the established factors for MACE in general (age, diabetes, significant coronary artery disease, and β-blocker) and the factors for vasospastic angina in particular (smoking, history of previous myocardial infarction).
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occurrence of MACE. When the occurrence of MACE was compared among the 1,349 VSA patients treated with a single CCB, we again found that MACE occurred significantly less in the benidipine group (n=219) as compared with the diltiazem group (n=788) (P=0.034, log-rank test) ( Figure 4A) . We calculated the propensity score, 11 using the selection criteria for each agent to correct the bias of patients background. The factors of selection criteria included age, sex, hypertension, hyperlipidemia, and previous MI, and matching was performed. After correction by the propensity score, there was no significant difference in any factors among the 4 CCB groups, and again the incidence of MACE in the benidipine group (n=204) was significantly lower as compared with the diltiazem (n=203, P<0.001) and the amlodipine groups (n=148, P=0.042) ( Figure 4B) .
Discussion
The present meta-analysis with a total of 1,997 Japanese patients with VSA revealed positive coronary spasm provocation tests demonstrates that among the major CCB used for the treatment of VSA, benidipine might exert more beneficial prognostic effects as compared with other CCB. To the best of our knowledge, this is the first meta-analysis study that addresses the comparative prognostic effects of CCB in VSA patients.
Clinical Significance of Meta-Analysis for the Prognosis of VSA Patients
There have been several reports regarding the prognostic effects of CCB in patients with VSA. 8-14 However, all of these studies were retrospective in nature and therefore there could be some bias introduced when doctors chose the drugs. Nevertheless, these retrospective studies are valuable because they provide important data with VSA patients treated with different kinds of drugs. Moreover, although randomized controlled studies are considered superior to retrospective studies, one cannot exclude the bias introduced when doctors choose the patients to be enrolled. Therefore, we endeavored to evaluate the effects of CCB on the occurrence of MACE in a meta-analysis by using raw data and re-defining the study endpoint.
Prognostic Factors for the Incidence of MACE in VSA Patients
The present meta-analysis showed that diabetes mellitus, the presence of CAD, use of β-blockers and advanced age (every 10 years) were significant risk factors for MACE in VSA patients ( Table 4) . It was previously reported that the age older than 65 years was a risk factor for cardiovascular events. 10 However, in the present study, we found that advanced age, even less than 65 years, was a risk factor for MACE in VSA patients. Diabetes mellitus is an established risk factor for cardiovascular events in VSA patients, 10,11 and insulin resistance associated with compensatory hyperinsulinemia is an independent risk factor for VSA. 16 Consistent with these findings, we found that diabetes mellitus is a risk factor for MACE. Indeed, the number of diabetic patients has been dramatically increasing in Japan, 17 indicating that special attention should be paid to diabetes mellitus in order to improve the prognosis of VSA patients.
It was repeatedly demonstrated that CAD is a prognostic factor in patients with rest angina and VSA. 1,10,11,13,18 Among these studies, Yamagishi et al emphasized that CAD is the most important prognostic factor affecting the prognosis of VSA patients, irrespective of the treatment with CCB. 18 The findings of the present study confirm that the risk of MACE is significantly increased by the presence of CAD, even in patients treated with CCB. Our findings also suggest the use of β-blockers might worsen the prognosis of VSA patients, which is consistent with an earlier report suggesting that β-blockers can worsen coronary vasospasm, 15 
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augmenting the effects of α-receptor stimulation. 19 In the present study, multivariate analysis showed that diabetes mellitus and CAD were independent risk factors for MACE, although age and use of β-blockers had no significant impact on the occurrence of MACE. We also confirmed that the risk of cardiovascular events, such as sudden death, fatal and non-fatal MI, increased in VSA patients with significant coronary stenosis. Thus, careful observation is necessary for diagnosis and treatment of diabetes mellitus in VSA patients.
Prognostic Effects of CCB in VSA Patients
CCB are usually prescribed to VSA patients in an effort to prevent attacks of coronary vasospasm and related sudden cardiovascular death and other cardiac events. 7,9-14, 18 However, only a few studies have compared the prognostic effects of CCB. 10-14 In these reports, the number of patients treated with CCB might not be high enough to draw a clear conclusion as to their prognostic effect in VSA patients. In the present study, we compared the prognostic effects of the 4 major CCB in a larger number of patients through a metaanalysis of the raw data. The result showed that benidipine had a significantly better prognostic effect as compared with amlodipine, nifedipine or diltiazem, while no differences were noted among the other 3 CCB.
Benidipine has been reported to be more selective for coronary artery smooth muscle cells compared with the other 3 CCB. 20,21 This higher selectivity of benidipine for coronary arteries might be involved not only in its inhibitory effects on coronary artery spasm, but also in its better prognostic effects. Moreover, the high affinity of benidipine for the coronary artery 22 might relate to its long-lasting effects independent of its blood concentration. 23 The beneficial prognostic effect of benidipine as compared with other CCB was first noted at sixth year, suggesting that vasculoprotective effects of but not anti-vasospastic effects of benidipine are involved (Figure 2) . Indeed, it was recently shown that benidipine, but not diltiazem, improves vascular endothelial function assessed by flow-mediated dilation (FMD) in VSA patients 24 and that benidipine improves vascular functions, including FMD, 25 pulse wave velocity 26 and augmentation index 27 in patients with hypertension. We also previously reported that benidipine reduced MI size by increasing nitric oxide (NO) production and inhibiting free radical production in a rabbit model of MI. 28 It was reported that changing from diltiazem to benidipine reduced the frequency of anginal attacks associated with increased plasma NO levels in VSA patients. 29 
Study Limitations
The apparent limitation of the present study is that it is a meta-analysis of the retrospective cohort studies with VSA patients, where all of the patients were prescribed a CCB, at least at the time of follow-up investigation. However, we were unable to confirm treatment compliance (eg, the rate of drug cessation during the follow-up period) due to the unavailability of such data from the 4 studies.
Although the patient characteristics were corrected by propensity score matching in the present study, a prospective randomized controlled clinical trial should be conducted to compare the prognostic effects of CCB in patients with VSA. Furthermore, the information on the type of long-acting nifedipine (eg, twice a day type or once a day type) was unavailable in the present study. This point also remains to be examined in a future study.
Conclusions
The present meta-analysis with 1,997 VSA patients demonstrates that benidipine exerts more beneficial prognostic effects in Japanese patients with VSA as compared with the other 3 CCB, although this notion remain to be confirmed in future prospective randomized studies.
